Cardiology Research and Practice最新文献

{"title":"Flow-Mediated Dilatation in the Assessment of Coronary Heart Disease: A Meta-Analysis.","authors":"Xiaoyong Xiao,&nbsp;Xian Li,&nbsp;Xiaohua Xiao,&nbsp;Jingjing Wang,&nbsp;Dehong Liu,&nbsp;Zhe Deng","doi":"10.1155/2022/7967324","DOIUrl":"https://doi.org/10.1155/2022/7967324","url":null,"abstract":"<p><p>Endothelial dysfunction may contribute to the increased morbidity and mortality associated with coronary heart disease (CHD). Flow-mediated dilatation (FMD) is the most popular noninvasive method for vascular endothelial function evaluation. This meta-analysis aimed to investigate the association between FMD and CHD. We searched the publications listed in the PubMed, Web of Science, Scopus, and Embase databases. Stata 14 software was used to analyze the data. Standardized mean difference (SMD) was used to calculate FMD levels, and the effect sizes were expressed with a 95% confidence interval (CI). I² statistics were used to evaluate statistical heterogeneity. In this meta-analysis, 9 studies enrolled a total number of 943 participants, including 534 (56.63%) patients with CHD and 409 controls (43.37%). We found that patients with CHD showed a significantly lower FMD than the controls (SMD -0.706%; 95% CI: -0.985, -0.427; <i>P</i>=0.001) with high heterogeneity. In addition, funnel plot analysis suggested asymmetry that could be evidence of publication bias. But sensitivity analyses show that there were no influential studies. This meta-analysis provides evidence that patients with CHD show a significantly lower FMD than controls and highlights the literature on FMD as a hallmark in CHD diseases.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"7967324"},"PeriodicalIF":2.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33498197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitral Annular Plane Systolic Excursion (MAPSE) as a Predictor of Atrial Fibrillation Recurrence in Patients after Pulmonary Vein Isolation.","authors":"Jan Alatic,&nbsp;David Suran,&nbsp;Damijan Vokac,&nbsp;Franjo Husam Naji","doi":"10.1155/2022/2746304","DOIUrl":"https://doi.org/10.1155/2022/2746304","url":null,"abstract":"<p><strong>Introduction: </strong>Catheter ablation (CA) with pulmonary vein isolation (PVI) has become widely used in the past years for the treatment of atrial fibrillation (AF). Mitral annular plane systolic excursion (MAPSE) is the parameter that measures left ventricular longitudinal function, and it appears to be a good early marker of LV dysfunction. It is practically independent of poor image quality. The aim of our study was to analyse the role of echocardiographic variables, especially MAPSE in predicting the outcome of CA in patients with AF.</p><p><strong>Materials and methods: </strong>We prospectively included 40 patients with paroxysmal and persistent AF that were referred for CA. All patients underwent radiofrequency CA with PVI. Standard transthoracic two-dimensional echocardiography was conducted one day after CA. Demographic data and the patients' characteristics were noted. The endpoint of our study was to estimate the AF recurrence rate diagnosed by ECG within 6 months of the follow-up period.</p><p><strong>Results: </strong>40 patients, mainly male (67.5%) with an average age of 61.43 ± 8.96 years were included in our study. The majority of patients had paroxysmal AF prior to ablation (77.5%). The AF recurrence rate was 20% after 6 months of follow-up. Lateral MAPSE in the AF-free group was greater than those who relapsed (1.57 ± 0.24 vs. 1.31 ± 0.25; <i>p</i> = 0.012). Patients who remained AF-free after a 6-month follow-up period had a significantly smaller left ventricular volume index (LAVI) than those who relapsed (34.29 ± 6.91 ml/m² vs. 42.90 ± 8.43 ml/m²; <i>p</i> = 0.05). We found a significant reverse relationship between LAVI and MAPSE (<i>p</i> = 0.020).</p><p><strong>Conclusion: </strong>MAPSE and LAVI present risk factors for AF recurrence, specifically reduced MAPSE and larger LAVI, are related to AF recurrence after CA. In the future, MAPSE could play a significant role when predicting the CA outcome in patients with AF.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"2746304"},"PeriodicalIF":2.1,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33509495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-<i>κ</i>B and Activating Nrf2-HO-1 Pathways.","authors":"Ming Fang,&nbsp;Jun Luo,&nbsp;Xi Zhu,&nbsp;Yingbiao Wu,&nbsp;Xinming Li","doi":"10.1155/2022/8372707","DOIUrl":"https://doi.org/10.1155/2022/8372707","url":null,"abstract":"<p><strong>Background: </strong>Heart failure is a critical health problem worldwide, and cardiac hypertrophy is an important characteristic of heart failure. Bromodomain-containing protein 4 (BRD4) is involved in various cellular processes, including cardiac hypertrophy. This study aimed to investigate the mechanism underlying the effects of BRD4 on cardiac hypertrophy.</p><p><strong>Methods: </strong>Rat myoblast H9c2 cells were treated with angiotensin II (Ang II) to increase the mRNA and protein expressions of BRD4. BRD4 was silenced by small interfering RNA (siRNA) in H9c2 cells. Proteins involved in Nrf2-HO-1 pathway were determined by Western blot.</p><p><strong>Results: </strong>Our data suggest that BRD4 silencing attenuated Ang II, increased the percentage of TUNEL + cells and caspase-3 activity, increased oxidative stress, and increased the expression and content of pro-inflammatory cytokines. Mechanistically, we found that BRD4 silencing enhanced the protein expressions of Nrf2 and HO-1 and inhibited the TLR4 and phosphorylation of NF-kappa B in Ang II-stimulated H9c2 cells. TLR4 overexpression attenuated cardioprotection against Ang II by BRD4 silencing, including cardiac hypertrophy, oxidative stress, and inflammatory cytokine production. Additionally, TLR4 overexpression attenuated an increase in Nrf2 and HO-1 proteins and decreased phosphorylated NF-kappa B in H9c2 cells.</p><p><strong>Conclusion: </strong>Our results speculate that the BRD4/TLR4 axis might be a promising strategy for treating cardiovascular diseases with cardiac hypertrophy, including HF.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"8372707"},"PeriodicalIF":2.1,"publicationDate":"2022-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33515113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ascending Aorta Diameter Changes after Aortic Valve Replacement in Elderly Patients with Aortic Valve Stenosis.","authors":"Jiamiao Gong,&nbsp;Kang An,&nbsp;Hongyuan Lin,&nbsp;Jianfeng Hou","doi":"10.1155/2022/5509364","DOIUrl":"https://doi.org/10.1155/2022/5509364","url":null,"abstract":"<p><strong>Objective: </strong>To describe the natural history of the ascending aorta in elderly patients after aortic valve replacement (AVR) for aortic valve stenosis and to clarify the risk factors associated with the progression of the ascending aorta.</p><p><strong>Methods: </strong>This retrospective review included a total of 87 elderly patients who had undergone aortic valve replacement for severe aortic valve stenosis in Fuwai Hospital. The patients were categorized into two groups based on the height-based aortic height index (AHI) before AVR, as determined by echocardiography and computed tomography: Group <i>A</i> (<i>n</i> = 28) was defined as an AHI > 2.44 cm/m, and Group <i>B</i> (<i>n</i> = 59) was defined as an AHI ≤ 2.44 cm/m. The perioperative and follow-up data were collected, and a linear mixed-effect model was used to analyze and compare the change rate of the ascending aorta after AVR.</p><p><strong>Results: </strong>The mean follow-up period was 4.0 ± 1.3 years. The diameter of ascending aorta in group <i>A</i> increased from 37.2 ± 5.0 mm at discharge to 40.7 ± 4.7 mm at the last follow-up (<i>P</i>=0.001), while that of group <i>B</i> increased only from 33.3 ± 4.4 mm to 33.7 ± 4.1 mm (<i>P</i> > 0.05).The ascending aorta diameter expansive rate was 0.81 mm/year in group <i>A</i> and 0.14 mm/year in group <i>B</i>. The expansive rate was significantly greater in patients with an AHI>2.44 cm/m than in those with anything else (<i>P</i> = 0.009). A univariable linear mixed model analysis revealed that the AHI>2.44 cm/m was the only significant risk factor for ascending aortic dilatation rate after AVR. There were 4 patients who died in hospital and 11 late follow-up deaths. Particularly, there was no aortic event that occurred during follow-up.</p><p><strong>Conclusion: </strong>For elderly patients with aortic stenosis, the possibility of progressive ascending aortic dilatation after AVR demands regular follow-up, and AHI may be an important risk factor for the change rate of the diameter of the ascending aorta.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"5509364"},"PeriodicalIF":2.1,"publicationDate":"2022-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40371491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients.","authors":"Joel Rodríguez-Saldaña,&nbsp;Francisco Padilla-Padilla,&nbsp;Ernesto G Cardona-Muñoz,&nbsp;Yulia Romero-Antonio,&nbsp;María Marcela Arguedas-Núñez,&nbsp;José G Sander-Padilla,&nbsp;Alberto Martínez-Muñoz,&nbsp;Laura A Lugo-Sánchez,&nbsp;Ileana C Rodríguez-Vazquez,&nbsp;Jorge González-Canudas","doi":"10.1155/2022/9464733","DOIUrl":"https://doi.org/10.1155/2022/9464733","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular diseases are the leading cause of death worldwide. The combination of statins and cholesterol-absorption inhibitors promotes the decrease in risk factors, such as high concentrations of LDL (low-density lipoproteins). The aim of the study was to evaluate changes in the lipid profile and the effect on therapeutic goals, as well as the safety of dyslipidemia patients treated with Rosuvastatin/Ezetimibe (Trezete®).</p><p><strong>Materials and methods: </strong>A real-world evidence study was conducted with retrospective data collection through a review of clinical records from dyslipidemia patients treated with Trezete® in routine medical practice. Clinical records included results of biochemical markers before treatment and at least one follow up between weeks 8 and 16.</p><p><strong>Results: </strong>The study included 103 patients' clinical records (55.4% men) with a mean age of 56.0 ± 13.0 years. More than 57% of the patients had mixed dyslipidemia and a median disease progression of 3.1 (IQR, 1.5; 9.1) years. Regarding LDL concentrations, 72.8% of the patients achieved therapeutic goals according to cardiovascular risk (CVR), which was statistically significant. Similarly, 94.1% achieved goals for total cholesterol (<200 mg/dL) and 56.0% for triglycerides (<150 mg/dL), a <i>p</i> value <0.001. No cardiovascular events were observed.</p><p><strong>Conclusion: </strong>Trezete® shows an important clinical impact on CVR-related target markers during the treatment of dyslipidemia patients. It is relevant to mention that a significant percentage of patients achieved therapeutic goals during the first months of treatment. Fixed-dose combination therapy has shown to be as safe as monotherapy treatment. ClinicalTrials.gov Identifier: NCT04862962.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"9464733"},"PeriodicalIF":2.1,"publicationDate":"2022-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40371492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship between Serum CXCL8 and ET-1 Expression Levels and Sepsis Complicated with Heart Failure.","authors":"Jianlong Zhu,&nbsp;Changjun Song,&nbsp;Tingting Cai,&nbsp;Lulu Yi,&nbsp;Wei Zhang,&nbsp;Jing Zhong,&nbsp;Meirong Shen","doi":"10.1155/2022/8570486","DOIUrl":"https://doi.org/10.1155/2022/8570486","url":null,"abstract":"<p><strong>Objective: </strong>The objective is to investigate the relationship between sepsis complicated with heart failure and the expression levels of CXC chemokine ligand 8 (CXCL8) and endothelin-1 (ET-1).</p><p><strong>Methods: </strong>A total of 128 sepsis patients accepted by the Ganzhou People's Hospital from March 2019 to December 2021 were collected as observation objects, and they were separated into a simple sepsis group (86 cases) and a complicated heart failure group (42 cases) according to whether they were accompanied by heart failure or not. General data such as Sequential Organ Failure Assessment (SOFA) score and Acute Physiology and Chronic Health Evaluation II (APACHE II) were collected; the expression levels of serum CXCL8 and ET-1 were detected by enzyme-linked immunosorbent assay (ELISA); the cardiac function parameters such as left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac output (CO), and cardiac index (CI) were measured by color Doppler ultrasound; the correlation between serum CXCL8 and ET-1 expression levels with clinical data and cardiac function parameters in patients with sepsis complicated with heart failure was analyzed by the Pearson correlation; and the influencing factors of sepsis complicated with heart failure were analyzed by the logistic regression analysis.</p><p><strong>Results: </strong>The serum CXCL8 and ET-1 expression levels, SOFA score, and APACHE II score in the complicated heart failure group were higher than those in the simple sepsis group (<i>P</i> < 0.05), and LVEF, SV, CO, and CI in the complicated heart failure group were lower than those in the simple sepsis group (<i>P</i> < 0.05). Serum CXCL8 was positively correlated with ET-1 in patients with sepsis complicated with heart failure (<i>r</i> = 0.531, <i>P</i> < 0.05), and the two were positively correlated with SOFA score and APACHE II score (<i>P</i> < 0.05) and were negatively correlated with LVEF, SV, CO, and CI (<i>P</i> < 0.05). CXCL8 and ET-1 were independent risk factors for sepsis complicated with heart failure (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The expression levels of serum CXCL8 and ET-1 in sepsis patients with heart failure are significantly increased, and both are risk factors for heart failure in sepsis patients.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"8570486"},"PeriodicalIF":2.1,"publicationDate":"2022-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40352863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of TNF-<i>α</i> on CHD and the Relationship between TNF-<i>α</i> Antagonist and CHD in Rheumatoid Arthritis: A Systematic Review.","authors":"Yezhou Qian,&nbsp;Menghui Mao,&nbsp;Feige Nian","doi":"10.1155/2022/6192053","DOIUrl":"10.1155/2022/6192053","url":null,"abstract":"<p><p>Tumor necrosis factor-alpha (TNF-<i>α</i>) plays an important role in coronary heart disease (CHD), a chronic inflammatory process. Meanwhile, this pro-inflammatory factor is also involved in the pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA). Patients with RA correspond to a higher risk of CHD. TNF-<i>α</i> antagonist, one of the main treatments for RA, may reduce the risk of CHD in patients with RA. This review summarizes the pathogenesis of TNF-<i>α</i> in CHD and discusses the relationship between TNF-<i>α</i> antagonist and CHD in patients with RA.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2022 ","pages":"6192053"},"PeriodicalIF":2.1,"publicationDate":"2022-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9640549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Value of Serum YKL-40 and TNF-<i>α</i> in the Diagnosis of Acute ST-Segment Elevation Myocardial Infarction.","authors":"Caoyang Fang,&nbsp;Zhenfei Chen,&nbsp;Jing Zhang,&nbsp;Jianyuan Pan,&nbsp;Xiaoqin Jin,&nbsp;Mengsi Yang,&nbsp;Luyao Huang","doi":"10.1155/2022/4905954","DOIUrl":"https://doi.org/10.1155/2022/4905954","url":null,"abstract":"<p><strong>Background: </strong>Acute ST-segment elevation myocardial infarction (STEMI) is a serious cardiovascular disease that poses a great threat to the life and health of patients. Therefore, early diagnosis is important for STEMI patient treatment and prognosis. The purpose of this study was to investigate the value of serum YKL-40 and TNF-<i>α</i> in the diagnosis of STEMI.</p><p><strong>Methods: </strong>From October 2020 to February 2022, 120 patients with STEMI were admitted to the Chest Pain Center of the Second People's Hospital of Hefei, and 81 patients with negative coronary angiography were selected as the control group. Serum YKL-40 and TNF-<i>α</i> concentrations were measured by sandwich ELISA. Pearson correlation was used to analyze the correlation between serum YKL-40, TNF-<i>α</i>, and serum troponin I (cTnI) in STEMI patients; multivariate logistic regression analysis was used to screen independent risk factors for STEMI. Three diagnostic models were constructed: cTnI univariate model (model <i>A</i>), combined serum YKL-40 and TNF-<i>α</i> model other than cTnI (model <i>B</i>), and combined cTnI and serum YKL-40 and TNF-<i>α</i> model (model <i>C</i>). We assessed the clinical usefulness of the diagnostic model by comparing AUC with decision curve analysis (DCA).</p><p><strong>Results: </strong>Serum YKL-40 and TNF-<i>α</i> in the STEMI group were significantly higher than those in the control group (<i>P</i> < 0.001). On Pearson correlation analysis, there was a significant positive correlation between serum YKL-40, TNF-<i>α</i>, and cTnI levels in STEMI patients. Multivariate logistic regression analysis showed that serum YKL-40 and TNF-<i>α</i> were independent risk factors for the development of STEMI. The results of ROC analysis showed that the area under the curve (AUC) of serum YKL-40 for predicting the occurrence of STEMI was 0.704. The AUC of serum TNF-<i>α</i> for predicting the occurrence of STEMI was 0.852. The AUC of cTnI as a traditional model, model <i>A</i>, for predicting the occurrence of STEMI was 0.875. Model <i>B</i> predicted STEMI with an AUC of 0.851. The addition of serum YKL-40 and serum TNF-<i>α</i> to the traditional diagnostic model composed of cTnI constituted a new diagnostic model; that is, the AUC of model <i>C</i> for predicting the occurrence of STEMI was 0.930. Model <i>C</i> had a better net benefit between a threshold probability of 70-95% for DCA.</p><p><strong>Conclusion: </strong>In this study, we demonstrate the utility of serum YKL-40 and TNF-<i>α</i> as diagnostic markers for STEMI and the clinical utility of diagnostic models by combining serum YKL-40 and TNF-<i>α</i> with cTnI.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"4905954"},"PeriodicalIF":2.1,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40343515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesized 18-Lead Electrocardiogram in Diagnosing Posterior Stemi-Equivalent Acute Coronary Syndrome in Patients with NSTEMI.","authors":"Tomoki Horie,&nbsp;Rikuta Hamaya,&nbsp;Tomoyo Sugiyama,&nbsp;Hidenori Hirano,&nbsp;Masahiro Hoshino,&nbsp;Yoshihisa Kanaji,&nbsp;Tetsumin Lee,&nbsp;Taishi Yonetsu,&nbsp;Tetsuo Sasano,&nbsp;Tsunekazu Kakuta","doi":"10.1155/2022/9582174","DOIUrl":"https://doi.org/10.1155/2022/9582174","url":null,"abstract":"<p><strong>Objective: </strong>To assess the clinical utility of synthesized V7-V9 ST-segment elevation (sV7-9 STE) in patients with 12-lead-electrocardiogram (ECG)-based non-STE myocardial infarction (NSTEMI) in diagnosing left circumflex artery (LCx) STEMI-equivalent acute coronary syndrome (ACS).</p><p><strong>Background: </strong>The 12-lead-ECG is insufficient for diagnosing patients with ACS, especially those with an LCx culprit.</p><p><strong>Methods: </strong>We retrospectively examined 219 patients with NSTEMI who underwent synthesized 18-lead ECG acquisition on admission and urgent catheterization. Associations between baseline variables, including sV7-9 STE and LCx STEMI-equivalent ACS, were analyzed using logistic regression models and receiver operating characteristics. LCx-culprit ACS was defined as thrombolysis in myocardial infarction (TIMI) 0-1 flow. The association between sV7-9 STE and myocardial damage was also assessed.</p><p><strong>Results: </strong>The mean (SD) age of the population was 68.8 (12.0) years, and 81.7% were men. LCx-culprit NSTEMI occurred in 58 (26.5%) patients and 15 (6.8%) were LCx STEMI-equivalent. SV7-9 STE was observed in 16 patients (7.9%). SV7-9 STE was the sole significant predictor of LCx STEMI-equivalent ACS with an odds ratio of 19.0 (95% CI: 5.6-63.9, <i>p</i> < 0.001), area under the curve of 0.71 (95% CI: 0.58-0.84), sensitivity of 46.7%, and specificity of 95.6%. After adjustment for confounders, sV7-9 STE was significantly associated with a 308% (95% CI: 78-834%) increase in peak high-sensitivity cardiac troponin I (<i>p</i>=0.001).</p><p><strong>Conclusions: </strong>SV7-9 STE had sole preprocedural diagnostic utility in detecting LCx STEMI-equivalent ACS with greater myocardial damage among patients with 12 ECG-based NSTEMI. The use of synthesized extra leads on admission may help identify patients with NSTEMI requiring primary revascularization.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"9582174"},"PeriodicalIF":2.1,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33454703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Genetic Testing-Based Cardiac Rehabilitation Program in Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention.","authors":"Xing Yu,&nbsp;Yuxuan Fan,&nbsp;Xiaopeng Sun,&nbsp;Xiaojing Wang,&nbsp;Qi Guo,&nbsp;Zhiqing Fan","doi":"10.1155/2022/9742071","DOIUrl":"https://doi.org/10.1155/2022/9742071","url":null,"abstract":"Objective There can be extreme variability between individual responses to exercise training, and the identification of genetic variants associated with individual variabilities in exercise-related traits could guide individualized exercise programs. We aimed to screen the exercise-related gene sensitivity of patients with acute myocardial infarction after PCI by establishing the gene spectrum of aerobic exercise and cardiopulmonary function sensitivity, test the effect of individualized precision exercise therapy, and provide evidence for the establishment of a precision medicine program for clinical research. Methods Aerobic exercise- and cardiopulmonary function-related genes and single-nucleotide polymorphisms (SNPs) were obtained by data mining utilizing a major publicly available biomedical repository, the NCBI PubMed database. Biological samples from all participants underwent DNA testing. We performed SNP detection using Samtools. A total of 122 patients who underwent PCI were enrolled in the study. We screened the first 24 cases with a high mutation frequency for aerobic exercise- and cardiopulmonary function-related genes and the last 24 cases with a low mutation frequency and separated them into two groups for the exercise intervention experiment. Results In both the low mutation frequency group and the high mutation frequency group, after 8 weeks of exercise intervention, 6 MWT distance, 6 MWT%, VO2/kg at peak, and VO2/kg at AT were significantly improved, and the effect in the high mutation frequency group was significantly higher than that in the low mutation frequency group (6 MWT distance: 468 vs. 439, P=0.003; 6 MWT%: 85 vs. 77, P=0.002, VO2/kg at peak: 14.7 vs. 13.3, P=0.002; VO2/kg at AT: 11.9 vs. 13.3, P=0.003). Conclusions There is extreme variability between individual responses to exercise training. The identification of genetic variants associated with individual variabilities in exercise-related traits could guide individualized exercise programs. We found that the subjects with a high mutation frequency in aerobic exercise and cardiopulmonary function-related genes achieved more cardiorespiratory fitness benefits in the aerobic exercise rehabilitation program and provided evidence for the establishment of a precision medicine program for clinical research.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"9742071"},"PeriodicalIF":2.1,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33442178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}